Accordingly, patients with biochemical recurrence having the lowest PSA levels prior to PSMA PET/CT had the lowest detection rate (55.1%) compared to patients with persistent (75%) or primary prostate cancer (100%). Here, FOLH1 is linked to prostate cancer.